Patritumab Deruxtecan Continues to Show Promising Clinical Activity in Patients Across Subtypes of Metastatic Breast or Lung Cancer
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic…
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic…
Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic…
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy…
SUWON, South Korea--(BUSINESS WIRE)--#ClinicalTrial--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today…
-Apical Wins Top Honours in ‘Land Use and Biodiversity’ and ‘Stakeholder Management’- JAKARTA, INDONESIA -…
KUALA LUMPUR, MALAYSIA - Media OutReach - 3 June 2022 - XLD Finance, a stablecoin-based…
SINGAPORE - Media OutReach - 3 June 2022 - NTUC LearningHub (NTUC LHUB), Singapore's leading…
More information available at www.ProtectFujitec.com HONG KONG & TOKYO--(BUSINESS WIRE)--Oasis Management Company Ltd. (“Oasis”) is…
SINGAPORE - Media OutReach - 3 June 2022 - ICS is a cancer management centre…
World's youngest allosaurus ever found Scavenger and pack hunter is considered the "bad boy" of…